Compare PZZA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | XERS |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | PZZA | XERS |
|---|---|---|
| Price | $34.80 | $6.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $45.00 | $10.83 |
| AVG Volume (30 Days) | 665.1K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,068,421,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | $39.59 | ★ N/A |
| Revenue Growth | 14.07 | ★ 142.67 |
| 52 Week Low | $30.16 | $4.26 |
| 52 Week High | $55.74 | $10.08 |
| Indicator | PZZA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 58.17 |
| Support Level | $30.47 | $6.26 |
| Resistance Level | $34.89 | $6.41 |
| Average True Range (ATR) | 1.41 | 0.20 |
| MACD | -0.29 | 0.03 |
| Stochastic Oscillator | 9.04 | 82.77 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.